Stock Events

Stock Events

Evolus 

€4.43
39
+€0.01+0.14% Monday 06:03

Statistics

Day High
4.43
Day Low
4.43
52W High
10.5
52W Low
3.52
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5AugExpected
Q4 2025
Q1 2026
Next
-0.1
-0.05
-0.01
0.04
Expected EPS
-0.03264814123
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EVL.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap277.02B
Merck & Co., through its acquisition of companies and products, competes in the aesthetics and dermatology space, potentially overlapping with Evolus's market.
GSK
GSK
Mkt Cap103.01B
GlaxoSmithKline, a large pharmaceutical company, has a diverse portfolio that includes products competing in the aesthetics space.
Pfizer
PFE
Mkt Cap149.77B
Pfizer, with its broad range of healthcare products, competes in various segments, including those that overlap with Evolus's interests.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie, after acquiring Allergan, directly competes with Evolus in the cosmetic injectable market, particularly with its Botox product.
State Street Global Allocation
GAL
Mkt Cap0
Galderma, a company specializing in dermatological treatments, offers a range of products that compete in the same space as Evolus's offerings.
Revolve Group
RVLV
Mkt Cap1.79B
Revolve, while primarily known for its fashion retail, has ventured into beauty and skincare products that could indirectly compete with Evolus.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson, through its wide range of healthcare products, has interests in the dermatology and aesthetics market, competing with Evolus.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap40.7B
Teva Pharmaceutical Industries, with its generic and specialty medicines, competes in the broader pharmaceutical market, including areas relevant to Evolus.
Novartis
NVS
Mkt Cap279.67B
Novartis, a global healthcare company, has a diverse portfolio that includes dermatology and aesthetics, competing with Evolus in certain markets.

About

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Show more...
CEO
Mr. David Moatazedi
Employees
213
Country
United States
ISIN
US30052C1071

Listings

MU
DE
EVL.MU
LSE
GB
0K16.LSE
STU
DE
EVL.STU
F
DE
EVL.F

0 Comments

Share your thoughts

FAQ

What is Evolus stock price today?▼
The current price of EVL.MU is €4.43 EUR — it has increased by +0.14% in the past 24 hours. Watch Evolus stock price performance more closely on the chart.
What is Evolus stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Evolus stocks are traded under the ticker EVL.MU.
Is Evolus stock price growing?▼
EVL.MU stock has fallen by -0.89% compared to the previous week, the month change is a +22.38% rise, over the last year Evolus has showed a -57.81% decrease.
When is the next Evolus earnings date?▼
Evolus is going to release the next earnings report on August 05, 2026.
What were Evolus earnings last quarter?▼
EVL.MU earnings for the last quarter are -0.04 EUR per share, whereas the estimation was -0.1 EUR resulting in a +59.41% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Evolus have?▼
As of May 06, 2026, the company has 213 employees.
In which sector is Evolus located?▼
Evolus operates in the Other sector.
When did Evolus complete a stock split?▼
Evolus has not had any recent stock splits.
Where is Evolus headquartered?▼
Evolus is headquartered in Newport Beach, United States.